Khiron Life Sciences Agrees to $500,000 Secured Deposit
Khiron Life Sciences Agrees to $500,000 Secured Deposit
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.Toronto, Ontario--(Newsfile Corp. - June 5, 2023) - Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQB: KHRNF) ("Khiron" or the "Company") announced today that the Company has agreed to a $500,000 non-interesting bearing refundable deposit from 2518542 Alberta Ltd. ("251"), a company controlled by Avonlea-Drewry Holdings Inc., to be secured by all of Khiron's present and after-acquired property pursuant to a general security agreement and a pledge of Khiron's shares in its subsidiaries, Pharmadrug Production GmbH and Zerenia Clinics UK Limited (the "Deposit").
安大略省多倫多-(Newsfile Corp.-2023年6月5日)-凱龍生命科學公司(多倫多證券交易所股票代碼：KHRN)(OTCQB：KHRNF)(“希龍“或”公司“)今天宣佈，公司已同意2518542艾伯塔省有限公司提供500,000美元的非利息可退還押金。251)，一家由Avonlea-Drewry Holdings Inc.控制的公司，將根據一般擔保協定和Khron在其子公司Pharmadrug Production GmbH和Zerenia Clinics UK Limited的股份質押，以Khron目前和收購後的所有財產為抵押。存款“)。
The Deposit is to be advanced to the Company pursuant to the terms and conditions of a letter of intent between, among others, Khiron and 251, whereby Khiron has granted 251 the exclusive right to negotiate the terms and conditions for the possible sale and acquisition of Khiron's European subsidiaries (the "Proposed Transaction"). The completion of the Proposed Transaction is subject to, among other things, the negotiation of a definitive purchase agreement and the receipt of all necessary regulatory approvals including the approval of the TSX Venture Exchange. If the Proposed Transaction is completed, then the full amount of the Deposit will be set off against the aggregate purchase price for the assets. There can be no assurance that the Proposed Transaction will be completed if at all and in the event that such Proposed Transaction is not completed, then the Company will be required to repay the Deposit.
定金將根據Khron與251等公司之間的意向書的條款和條件預付給本公司，根據該意向書，Khron已授予251獨家權利，就可能出售和收購Khron的歐洲子公司的條款和條件進行談判。建議的交易“)。建議交易的完成，除其他事項外，須視乎最終購買協定的談判及所有必要的監管批准，包括多倫多證券交易所創業板的批准。如果建議交易完成，則按金將全數抵銷資產的總購買價。不能保證建議交易將會完成，若建議交易未能完成，本公司將被要求償還按金。
Further details, including the definitive terms of the Proposed Transaction, will be provided by Khiron in a subsequent news release.
更多細節，包括擬議交易的最終條款，將由Khron在隨後的新聞稿中提供。
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
多倫多證券交易所風險交易所及其監管服務提供商(該術語在多倫多證券交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。
About Khiron Life Sciences Corp.
Khiron is a leading global medical cannabis company with core operations in Latin America and Europe. Leveraging wholly owned medical health clinics and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific expertise, product innovation, and focus on creating access to drive prescriptions and brand loyalty with patients worldwide. The Company has a sales presence in Colombia, Germany, the United Kingdom, Switzerland, Peru, and Brazil. The Company is led by its co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and diverse executive team and board of directors.
關於Khron生命科學公司
科龍公司是一家全球領先的醫用大麻公司，核心業務在拉丁美洲和歐洲。利用全資擁有的醫療保健診所和專有的遠端醫療平臺，Khron將以患者為中心的方法、醫生教育計劃、科學專業知識、產品創新結合在一起，並專注於創建渠道，以推動處方和全球患者的品牌忠誠度。該公司在哥倫比亞、德國、英國、瑞士、祕魯和巴西設有銷售機構。該公司由其聯合創始人兼首席執行官阿爾瓦羅·託雷斯領導，以及一支經驗豐富和多元化的管理團隊和董事會。
Contact:
聯繫方式：
Alvaro Torres
Chief Executive Officer
Tel: +57 17442064
阿爾瓦羅·託雷斯
首席執行官
電話：+57 17442064
Investor Contact:
E: investors@khiron.ca
投資者聯繫方式：
E：Investors@khiron.ca
Media Contact:
Peter Leis, Europe Communications
E : pleis@khiron.ca
媒體聯繫人：
彼得·萊斯，歐洲通訊部
E：pleis@khiron.ca
Cautionary Statement Regarding Forward-Looking Statements
警示聲明：前瞻性陳述
This press release contains "forward-looking information" within the meaning of applicable Canadian securities laws (collectively, "forward-looking information"). Forward-looking information are often, but not always, identified by the use of words such as "seek", "anticipate", "believe", "plan", "estimate", "expect", "likely" and "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. Forward-looking information in this press release includes, without limitation, statements relating to the advance of the Deposit, the proposed sale of Khiron's European subsidiaries including the negotiation of a definitive purchase agreement for the Proposed Transaction and the satisfaction or repayment of the Deposit.
本新聞稿包含適用的加拿大證券法(統稱為，前瞻性資訊“)。前瞻性資訊常常但不總是通過使用諸如“尋求”、“預期”、“相信”、“計劃”、“估計”、“預期”、“可能”和“打算”等詞語，以及事件或結果“可能”、“將”、“應該”、“可能”或“可能”發生或可能實現以及其他類似表述來確定。本新聞稿中的前瞻性資訊包括但不限於有關預付定金、擬出售Khron歐洲子公司的陳述，包括就擬議交易的最終購買協定的談判，以及定金的償付或償還。
The forward-looking information is subject to known and unknown risks, uncertainties, and other factors, many of which are beyond the control of management, that may cause actual results to differ materially from those expressed or implied in such forward-looking information. Such risks and uncertainties include but are not limited to the following: the failure of the parties to successfully negotiate a definitive purchase agreement for the Proposed Transaction, the failure to obtain all the required regulatory requirements and approvals including the approval of the TSXV and adverse changes in general economic conditions.
前瞻性資訊受到已知和未知的風險、不確定性和其他因素的影響，其中許多因素不是管理層所能控制的，這些因素可能會導致實際結果與前瞻性資訊中明示或暗示的結果大不相同。此類風險和不確定性包括但不限於：各方未能就擬議交易成功談判達成最終採購協定，未能獲得所有必要的監管要求和批准，包括多倫多證券交易所的批准，以及總體經濟狀況的不利變化。
As a result of the foregoing and other risks and uncertainties, readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.
由於上述和其他風險和不確定性，提醒讀者仔細考慮這些和其他因素、不確定性和潛在事件，不要過度依賴前瞻性資訊。本文中包含的前瞻性資訊是在本新聞稿發佈之日作出的，是基於管理層在作出這些前瞻性資訊之日的信念、估計、預期和意見。除適用法律要求外，公司沒有義務更新或修改任何前瞻性資訊，無論是由於新的資訊、估計或意見、未來事件或結果或其他原因，也沒有義務解釋後續實際事件與此類前瞻性資訊之間的任何重大差異。
To view the source version of this press release, please visit
要查看本新聞稿的源版本，請訪問
譯文內容由第三人軟體翻譯。